Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen

Bone Marrow Transplantation

Volumn 40, Issue 1, 2007, Pages 19-27

  Dey, B R ^a   Shaffer, J ^a   Yee, A J ^a   McAfee, S ^a   Caron, M ^a   Power, K ^a   Ting, D T ^a   Colby, C ^a   Preffer, F ^a   Ballen, K ^a   Attar, E ^a   Saidman, S ^a   Tarbell, N ^a   Sachs, D ^a   Sykes, M ^a   Spitzer, T R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPHIL COUNT; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; FAMILY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34347375338     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705688     Document Type: Article

References (46)

1. Dreger P, Oberboster K, Schmitz N. PBPC grafts from healthy donors: analysis of CD34+ and CD3+ subpopulations. Bone Marrow Transplant 1996; 17 (Suppl 2): S22-S27.
2. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33-41.
3. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stemcells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
4. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 2000; 355: 1231-1237.
5. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
6. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
7. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-767.
8. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies Canadian Bone Marrow Transplant Group. Blood 2002; 100: 1525-1531.
9. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655-4664.
10. Tanimoto TE, Yamaguchi T, Tanaka Y, Saito A, Tajima K, Karasuno T et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004; 125: 480-493.
11. Scmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. A randomized study from European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilized peripheral blood progenitor cells with bone marrow transplantation in 350 patients with leukemia. Blood 2000; 96 481a.
12. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
13. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
14. Giralt S, Estey E, Albitar M, van Besien K, Rondon G,Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
15. Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D et al. Successful allogeneic stemcell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604-612.
16. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-4000.
17. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
18. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783-787.
19. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133-143.
20. Mapara MY, Yong-Mi K, Sheng-Ping W, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909.
21. Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-vs-host disease, and anti-tumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320-329.
22. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22 1145-1151.
23. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R et al. A randomised study of allogeneic transplantation with stem cells from blood or bonemarrow. Bone Marrow Transplant 2000; 25 1129-1136.
24. Kraus AB, Shaffer J, Toh HC, Preffer F, Dombkowski D, Saidman S et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2003; 31: 609-621.
25. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
26. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101-109.
27. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
28. Liu YJ, Blom B. Introduction: TH2-inducing DC2 for immunotherapy. Blood 2000; 95: 2482-2483.
29. Sloand EM, KimS, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo Blood 2000; 95: 2269-2274.
30. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002; 100: 2562-2571.
31. Morris ES, MacDonald KP, Rowe V, Johnson DH, Banovic T, Clouston AD et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004; 103: 3573-3581.
32. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001; 19: 3685-3691.
33. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
34. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
35. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990; 6: 283-289.
36. Mohty M, Gaugler B. Dendritic cells: Interfaces with immunobiology and medicine. A report from the Keystone Symposia Meeting held in Keystone, 3-8 March 2003. Leukemia 2003; 17: 1753-1758.
37. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34(+) selected cells fromperipheral blood from human leukocyte antigen-identical siblings: Detrimental effect of a high number of donor CD34(+) cells? Blood 2001; 98: 2352-2357.
38. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stemcell transplantation. Blood 2003; 102: 1108-1113.
39. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775-2779.
40. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97 3380-3389.
41. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5: 83-89.
42. Mclean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 1995; 92 3707-3711.
43. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360: 264-265.
44. van Rhee F, Jiang YZ, Vigue F, Kirby M, Mavroudis D, Hensel NF et al. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: Implications for graft rejection in mismatched transplantation. Br J Haematol 1999; 105: 1014-1024.
45. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M et al. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998; 22: 631-637.
46. Ryncarz RE, Anasetti C. Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood 1998; 91: 3892-3900.